Opendata, web and dolomites

MP-101

a novel drug for prevention and treatment peripheral neuropathy symptoms

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MP-101 project word cloud

Explore the words cloud of the MP-101 project. It provides you a very rough idea of what is the project "MP-101" about.

moderately    causing    fact    gain    glutamate    suffering    nervous    neuropathy    50x    immuno    chain    prolonged    damage    sales    brain    6m    treat    signaling    scaling    drugs    patients    unpleasant    painkiller    risks    excessive    2m    101    18m    life    central    spine    strategy    quality    market    strength    combination    chemotherapeutic    clinical    treatment    lowering    agents    patient    lasting    impeding    leads    trials    stop    sensitization    neuropathic    regulatory    regardless    none    innovation    stimulation    big    alone    metys    modulator    symptoms    pharmaceuticals    pain    there    drafted    eurotransmitter    painful    excitation    cancer    plan    dependent    therapies    mp    prevention    oncology    prematurely    diminishing    acts    normal    worldwide    constant    approval    world    difficult    endings    cipn    nerves    20181    sensory    diagnosed    preventing    troublesome    submitting    7m    people    estimate    peripheral    nerve    chemotherapy    sedating    performing    40    supply    group    substantial   

Project "MP-101" data sheet

The following table provides information about the project.

Coordinator
METYS PHARMACEUTICALS AG 

Organization address
address: GERBERGASSE 30
city: BASEL
postcode: 4001
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://metys-pharma.ch/en/about
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    METYS PHARMACEUTICALS AG CH (BASEL) coordinator 50˙000.00

Map

 Project objective

There will be over 18m new cases of cancer worldwide in 20181, out of which about 3,7m in Europe alone. Studies estimate that up to 40% of all cancer patients develop chemotherapy-induced peripheral sensory neuropathy (CIPN), meaning over 1,6m patients in EU and 7,2m world-wide may experience CIPN each year. This group is only growing in number, due to the constant growth in new cases of diagnosed cancer. The new immuno-oncology drugs are increasingly being used in combination with chemotherapy. CIPN is a condition that affects the peripheral nervous system, leading to long-lasting, painful, and difficult-to-treat symptoms in the central nervous system, lowering the patient’s life quality and impeding patient’s normal activities. In fact, the CIPN induced pain is so strong and troublesome that many patients stop their cancer chemotherapy treatment prematurely. Regardless of the big and increasing number of people suffering from CIPN, only moderately effective therapies are available for the treatment, none specifically developed for CIPN, with substantial risks and unpleasant side effects for patients. Metys Pharmaceuticals is developing MP-101 - a novel, non-sedating, painkiller for prevention and for treatment of CIPN-associated neuropathic pain. Chemotherapeutic agents damage peripheral nerve endings, causing excessive signaling and sensitization which involves the eurotransmitter glutamate: this leads to prolonged excitation of the central nerves of the spine and brain. MP-101 acts as glutamate modulator, diminishing the strength of glutamate stimulation, or, if given early enough, preventing glutamate-dependent sensitization. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. The innovation project will focus on scaling up the production by 50x, performing phase 2 clinical trials, before submitting results to gain regulatory approval for sales across Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MP-101" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MP-101" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More